Phanes Therapeutics
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Oncology
Phanes Therapeutics is a San Diego–based, clinical-stage immuno-oncology company advancing a wholly owned portfolio of differentiated antibody therapeutics for solid tumors. Phanes is conducting Phase 1/2 trials across three in-house developed programs. The most advanced asset spevatamig, a first-in-class CLDN18.2 × CD47 bispecific antibody developed using Phanes' proprietary technology platforms, has demonstrated positive Phase 2 results in first-line metastatic pancreatic ductal adenocarcinoma. Peluntamig, a DLL3 × CD47 bispecific, is in clinical development for small cell lung cancer and neuroendocrine carcinomas. Both programs have received FDA Fast Track and Orphan Drug designations. Mavrostobart, a best-in-class anti-CD73 monoclonal antibody, further expands Phanes' differentiated immuno-oncology pipeline.
Company HQ City:
San Diego
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2016
Lead Product in Development:
spevatamig
CEO
Ming Wang
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
August 2026
What is your next catalyst (value inflection) update?
Phase 2 data readout for pancreatic cancer
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}